DE-ADCC/CDC FUNCTIONS OF ANTIBODIES AND THEIR APPLICATIONS

Abstract

The present invention provides De-ADCC/CDC activity monoclonal antibodies and their generation method and applications. The present invention modified the antibody sequences of multi-target sites such as PD-L1, PD-1, CTLA4, TNF-α, PCSK9, NGF, CD47 and C5. A flexible amino acid sequence was inserted between the heavy chain CDR3 and CH2 regions of IgG1 antibody to block the physical stress signal transmit from antigen-bound Fab to its Fc region to reduce the ADCC/CDC activity while not significantly increasing the formation of the polymers. The modified antibodies in the present invention and the original antibodies target the same sites, but the antibody subtype or glycosylation state is different. For the modified antibodies in the present invention, the stability is significantly improved or/and immunogenicity is significantly reduced, and the half-life is prolonged. The modified antibodies eliminate the activity of ADCC/CDC. Therefore, the antibody modified by the technology of the present invention can effectively avoid side effects caused by the activation of ADCC/CDC and other Fc-mediated functions and improve the curative effect of antibody drugs. It has excellent clinical application value and is suitable for promotion.

Claims

1. A method of reducing or removing the ADCC/CDC and other Fc-mediated activities of an IgG1 isoform antibody achieved by insertion of a flexible amino acid sequence in a constant region of a heavy chain of the IgG1 subtype antibody to stop stress transmission of conformation change.

2. The method described in claim 1, characterized by insertion of a flexible amino acid sequence between the CDR3 and CH2 regions of the heavy chain of the IgG1 subtype antibody to stop stress transmission of conformation change.

3. The method of claim 1, characterized by at least one of the following: (i) insertion of a flexible amino acid sequence, blocking mechanical stress transmission from variable area to constant region after combining of antigen and the antibody; (ii) Fc and/or complement binding sites in heavy chain of the antibody is not sufficiently exposed to Fc receptor and/or complement without this stress transmission; (iii) insertion of the flexible sequence weakens or stops the interaction between the antibody and NK cells, macrophages or neutrophils, which express IgG Fc receptors or complement, leading to reduced or eliminated ADCC and CDC activity; (iv) modified antibodies, the subtype of which is IgG1, are anti-PD-L1, anti-PD-1, anti-CTLA-4, anti-TNF-α, anti-PCSK9, anti-NGF, anti-05, anti-A (3, anti-IL-6, anti-IL-17A, anti-IL23A, anti-HGF, anti-CMET, anti-Notch1, anti-CCL11, anti-IL6R, anti-IL-31R, anti-IL-1B, anti-IL-20, anti-CD40, anti-CD47, anti-DKK1/2, anti-TIGIT, anti-4-1BB, anti-IGF-1R, anti-LL4, anti-PDGFR2, anti-HER3, anti-IGF1/2, anti-RANKL, anti-sclerostin, anti-GCGR, anti-CGRP, anti-ANGPTL3, anti-IL-13, anti-IL-4R, anti-CSF-1R, anti-TFPI, anti-FCGRT, anti-CD47 antibodies, such as Atezolizumab, Pembrolizumab, Ipilimumab, Eculizumab, evolocumab, erenumab, fulranumab, crenezumab, brodalumab, ixekizumab, satralizumab, gevokizumab, denosumab, blosozumab, crotedumab, fasinumab, fremanezumab, evinacumab, lebrikizumab, dupilumab, cabiralizumab, concizumab, rozanolixizumab, magrolimab, etc., or the IgG1 subtype modified antibody of an antibody drug mentioned above.

4. (canceled)

5. The method of claim 1, wherein the flexible amino acid sequence comprises a segment of connecting polypeptide consisting of amino acids with smaller side chains, which is used to prevent or reduce the interference on the structure conformation between the structural domains at its two ends, optionally including GGSGGS, GSGGSGG, GSGGSGGG, GGGGSGGG, GSGSG, GGSGG, GGS, GGSGS or GGGS.

6. De-ADCC/CDC antibodies, generated by any of the methods described in claim 1.

7. De-ADCC/CDC antibodies according to claim 6, wherein are characterized by being chimeric antibodies, humanized antibodies, fully human antibodies, bis-specific antibodies, or Fc-fusion proteins.

8. The De-ADCC/CDC antibodies according to claim 6, wherein the modified antibodies can be anti-PD-L1, anti-PD-1, anti-CTLA-4, anti-TNF-α, anti-PCSK9, anti-NGF, anti-C5, anti-Aβ, anti-IL-6, anti-IL-17A, anti-IL23A, anti-HGF, anti-CMET, anti-Notch1, anti-CCL11, anti-IL6R, anti-IL-31R, anti-IL-1B, anti-IL-20, anti-CD40, anti-CD47, anti-DKK1/2, anti-TIGIT, anti-4-1BB, anti-IGF-1R, anti-LL4, anti-PDGFR2, anti-HER3, anti-IGF1/2, anti-RANKL, anti-sclerostin, anti-GCGR, anti-CGRP, anti-ANGPTL3, anti-IL-13, anti-IL-4R, anti-CSF-1R, anti-TFPI, anti-FCGRT, anti-CD47 antibodies, wherein said antibodies optionally fulfill at least one of: (i) insertion of a flexible amino acid sequence between the CDR3 and CH2 regions of the heavy chain of the IgG1 subtype antibody; (ii) the flexible amino acid sequence used is a segment of connecting polypeptide consisting of amino acids with smaller side chains, which is used to prevent or reduce the interference on the structure conformation between the structural domains at its two ends, including GGSGGS, GSGGSGG, GSGGSGGG, GGGGSGGG, GSGSG, GGSGG, GGS, GGSGS or GGGS; (iii) they are used in a method in reducing or eliminating ADCC and CDC activity of IgG1 subtype antibodies.

9. (canceled)

10. A method for reducing or eliminating the ADCC/CDC activity of IgG1 subtype antibodies, the method comprising inserting a flexible amino acid sequence into the IgG1 antibodies, optionally into a constant region of a heavy chain of the IgG1 subtype antibodies, further optionally between CDR3 and CH2 regions of the heavy chain of the IgG1 antibodies.

11-12. (canceled)

13. The method of claim 10, wherein sites of inserting the flexible amino acid sequence include GG (138/139), SS (177/178), SG (178/179), SS (184/185), SSS (191/192/193), LL (235/236), GG (237/238.

14. (canceled)

15. A method for reducing ADCC and CDC activities and other Fc-mediated functions while also improving antibody stability, reducing antibody immunogenicity, or prolonging antibody half-life, wherein optionally, a flexible amino acid sequence is inserted into the constant region of an IgG1 antibody heavy chain, and further optionally the flexible amino acid sequence is inserted into a heavy chain of IgG1 antibody between CDR3 and CH2 regions, wherein the flexible amino acid sequence optionally includes GGSGGS, GSGGSGG, GSGGSGGG, GGGGSGGG, GSGSG, GGSGG, GGS, GGSGS or GGGS.

16. (canceled)

17. A De-ADCC/CDC anti-PD-L1 antibody characterized by: (i) the insertion of a flexible amino acid sequence, blocking the mechanical stress transmit from variable area to constant region after the combining of antigen and antibody; (ii) the Fc and/or complement binding sites in heavy chain of the antibody is not sufficiently exposed to Fc receptor and/or complement without this stress transmission; and/or (iii) the insertion of the flexible sequence can weaken the interaction between antibody and NK cells, macrophages or neutrophils, which express IgG Fc receptors or complement, leading to reduced or eliminated ADCC and CDC activity, wherein the De-ADCC/CDC anti-PD-L1 antibodies are optionally characterized by the insertion of a flexible amino acid sequence between the CDR3 and CH2 region of the heavy chain of IgG1 antibody to block the mechanical stress transmit from variable area to constant region after the combining of antigen and antibody, optionally the amino acid sequences of the heavy chain and the light chain of an original Atezolizumab comprising SEQ ID NO.1 and SEQ ID NO.2 respectively; (iv) the De-ADCC/CDC anti-PD-L1 antibodies, characterized by the full length amino acid sequence of light chain contain SEQ ID NO.2 or its variants, and the full length amino acid sequence of heavy chain contains any of the sequences in SEQ ID NO.3 or SEQ ID NO.4.

18-24. (canceled)

25. A De-ADCC/CDC anti-PD-1 antibody characterized by at least one selected from a group of: a insertion of a flexible amino acid sequence, blocking mechanical stress transmission from variable area to constant region after combining of antigen and the antibody; (ii) Fc and/or complement binding sites in heavy chain of the antibody not sufficiently exposed to Fc receptor and/or complement without stress transmission; (iii) insertion of a flexible sequence weakens interaction between the antibody and NK cells, macrophages or neutrophils, which express IgG Fc receptors or complement, leading to reduced or eliminated ADCC and CDC activity, wherein the antibody is optionally characterized by the insertion of an amino acid sequence between a CDR3 and CH2 regions of a heavy chain of IgG1 antibody to block mechanical stress transmission from variable area to constant region after combining of antigen and the antibody, further optionally the flexible amino acid sequences of the heavy chain and a light chain of an original Pembrolizumab comprising SEQ ID NO.5 and SEQ ID NO.6 respectively; and (iv) a full length amino acid sequence of light chain comprises SEQ ID NO.6, and a full length amino acid sequence of heavy chain comprises SEQ ID NO.7.

26-32. (canceled)

33. A De-ADCC/CDC anti-CTLA-4 antibody characterized by at least one selected from a group of: (i) insertion of a flexible amino acid sequence in a constant region of Ipilimumab, blocking mechanical stress transmission from variable area to constant region after combining of antigen and the antibody (ii) Fc and/or complement binding sites in heavy chain of the antibody is not sufficiently exposed to Fc receptor and/or complement without stress transmission; (iii) insertion of a flexible sequence weakens interaction between the antibody and NK cells, macrophages or neutrophils, which express IgG Fc receptors or complement, leading to reduced or eliminated ADCC and CDC activity, wherein the antibody is characterized by insertion of a flexible amino acid sequence between CDR3 and CH2 regions of a heavy chain of Ipilimumab to block a mechanical stress transmission from variable area to constant region after combining of antigen and the antibody, optionally amino acid sequences of the heavy chain and a light chain of an original Ipilimumab comprising SEQ ID NO.8 and SEQ ID NO.9 respectively; and (iv) a full length amino acid sequence of light chain comprises SEQ ID NO.9, and a full length amino acid sequence of heavy chain comprises SEQ ID NO.10.

34-35. (canceled)

36. Any gene coding De-ADCC/CDC anti-PD-L1, anti-PD-1 and anti-CTLA-4 antibodies as described in claim 6 for: (1) Application in the generation of drugs targeting PD-L1 PD-1 or CTLA-4, or other antigens; (2) Application in the treatment of diseases targeted by PD-L1 PD-1 or CTLA-4, or other antigens; (3) Application in the treatment of tumors or immunodegenerative diseases; (4) Application in the treatment of degenerative and other human diseases.

37-38. (canceled)

39. Any drug of the De-ADCC/CDC anti-PD-L1, anti-PD-1, anti-CTLA-4 and other antibody described in claim 6 for: (1) generation of drugs targeting PD-L1, PD-1 or CTLA-4, or other antigens; (2) Application in the treatment of diseases targeted by PD-L1, PD-1 or CTLA-4, or other antigens; (3) Applications in the treatment of tumors or immunodegenerative diseases; (4) Application in the treatment of degenerative and other human diseases.

40. (canceled)

Description

BRIEF DESCRIPTION OF THE DRAWINGS

[0114] FIG. 1 is the heavy chain sequence alignment of the modified PD-L1 monoclonal antibody (H-1L0 and H-2L0) and the original Atezolizumab.

[0115] FIG. 2 is the binding affinity of modified PD-L1 monoclonal antibody and the original Atezolizumab. The x-coordinate is the antibody concentration (M), and the y-coordinate is the absorbance at 450 nm.

[0116] FIG. 3 is the ADCC activity evaluation of modified PD-L1 monoclonal antibody (H-1L0 and H-2L0) and the original Atezolizumab measured by an in vitro cell killing assay using PD-L1 overexpressing Raji cells together with FcR overexpressing TANK cells in the presence or absence of PD-L1 antibodies. The x-coordinate is the sample concentration (ng/mL), and the y-coordinate is the percentage of lysed raji-PDL1 cells, the IMM25 is an ADCC-enhanced anti-PD-L1 antibody used as the positive control, and the original Atezolizumab was used as the control for ADCC evaluation.

[0117] FIG. 4 is the inhibitory activity of modified PD-L1 monoclonal antibody and the original Atezolizumab measured by in vitro cell-based Bioassay using Jurkat-PD-1-NFAT cell line that stably expresses PD-1 with the reporter luciferase gene. The x-coordinate is antibody concentration and the y-coordinate is mean value of the relative fluorescence units (RLU).

[0118] FIG. 5 is the ADA titers evaluation from the mice immunized with either modified PD-L1 monoclonal antibody or the original Atezolizumab measured using Indirect ELISA against antibody drugs. The x-coordinate is the serum dilution ratio and the y-coordinate is the absorbance value at 450 nm.

[0119] FIGS. 6A and 6B are graphs of the original Atezolizumab and the modified PD-L1 monoclonal antibody measured by HPLC-SEC.

[0120] FIGS. 7A and 7B are the glycon type analysis of the original Atezolizumab and the modified PD-L1 monoclonal antibody of the invention.

[0121] FIG. 8 is the thermal stability evaluation of the original Atezolizumab and the modified PD-L1 monoclonal antibody of the invention. The x-coordinate is the antibody concentration (M), and the y-coordinate is the absorbance at 450 nm. The H-1L0 stands for modified anti-PD-L1 antibody.

[0122] FIG. 9 is the heavy chain sequence alignment of the modified PD-1 monoclonal antibody and the original Pembrolizumab.

[0123] FIG. 10 is the binding affinity of modified PD-1 monoclonal antibody and the original Pembrolizumab. The x-coordinate is the antibody concentration (M), and the y-coordinate is the absorbance at 450 nm.

[0124] FIG. 11 is the ADCC activity evaluation of modified PD-1 monoclonal antibody and the original Pembrolizumab measured by an in vitro cell killing assay using PD-1 overexpressing Raji cells together with FcR overexpressing TANK cells in the presence or absence of PD-1 antibodies. The x-coordinate is the sample concentration (ng/mL), and the y-coordinate is the percentage of lysed raji-PD1 cells. Raji cell express CD20 on its membrane, so the Rituximab, which is an anti-CD20 antibody, can be used as positive control for ADCC evaluation.

[0125] FIG. 12 is the inhibitory activity of modified PD-1 monoclonal antibody and the original Pembrolizumab measured by in vitro cell-based Bioassay using Jurkat-PD-1-NFAT cell line that stably expresses PD-1 with the reporter luciferase gene. The x-coordinate is antibody concentration and the y-coordinate is the inhibition rate.

[0126] FIG. 13 is the heavy chain sequence alignment of the modified CTLA-4 monoclonal antibody and the original Ipilimumab.

[0127] FIG. 14 is the binding affinity of modified CTLA-4 monoclonal antibody and the original Ipilimumab. The x-coordinate is the antibody concentration (M), and the y-coordinate is the absorbance at 450 nm.

[0128] FIG. 15 is the ADCC activity evaluation of modified CTLA-4 monoclonal antibody and the original Ipilimumab measured by an in vitro cell killing assay using CTLA-4 overexpressing Raji cells together with FcR overexpressing TANK cells in the presence or absence of CTLA-4 antibodies. The x-coordinate is the sample concentration (ng/mL), and the y-coordinate is the percentage of lysed raji-PD1 cells.

[0129] FIG. 16 is the inhibitory activity of modified CTLA-4 monoclonal antibody and the original Ipilimumab measured by ELISA-based Bioassay. The x-coordinate is antibody concentration (M) and the y-coordinate is the absorbance value at 450 nm. The H1L0 stands for modified anti-CTLA-4 antibody.

[0130] FIG. 17 is the competition of antibodies with CD80 and CD86 to bind to human CTLA-4 expressed CHO cells. The x-coordinate is antibody concentration (M) and the y-coordinate is the absorbance value at 450 nm. The H1L0 stands for modified anti-CTLA-4 antibody.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

[0131] All references mentioned herein are specifically incorporated by reference.

Abbreviations and Definitions

[0132] “Antibody” means any form of an antibody that exhibits the biological activity required (for example, by inhibiting ligand binding to its receptor or by inhibiting ligand-induced receptor signaling). Therefore, the antibodies are used in the broadest sense and explicitly include, but are not limited to, monoclonal antibodies, polyclonal antibodies, and poly-specific antibodies.

[0133] The “Fab fragment” consists of the CH1 region of a light chain and a heavy chain as well as the variable region. The heavy chain of one Fab molecule cannot form the disulfide bond with that of another molecule.

[0134] The “Fc” region is the two heavy chain fragments containing the CH1 and CH2 domains of the antibodies. The two heavy chain fragments are held together by two or more disulfide bonds and by hydrophobic interaction in the CH3 domain.

[0135] The “Fab′ fragment” contains a light chain and a heavy chain that contains the VH domain, the CH1 domain and the region between CH1 and CH2 domains, thus an interchain disulfide bond can be formed between the two heavy chains of the two Fab′ fragments to form the F(ab′)2 molecule.

[0136] The term “monoclonal antibody” used in this application refers to antibodies derived from essentially homologous antibody groups, that is, the antibodies that make up the group are consistent except for possible natural mutations that may be present in small quantities. Monoclonal antibodies are highly specific and can target a single antigen site. Furthermore, in contrast to the conventional (polyclonal) antibody generation, which usually consists of several different antibodies against several different determinants (epitopes), each monoclonal antibody targets only a single determinant on an antigen. The term “monoclonal” denotes the characteristics of an antibody obtained from a substantially homoclonal antibody group and cannot be understood as requiring the generation of the antibody by any particular method.

[0137] The term “flexible amino acid sequence” used in this application refers to a segment of connecting polypeptide consisting of amino acids with smaller side chains, which is used to prevent or reduce the interference on the structure conformation between the structural domains at its two ends, including but not limited to GGSGGS, GSGGSGG, GSGGSGGG, GGGGSGGG, GSGSG, GGSGG, GGS, GGSGS and GGGS.

[0138] The term “immune cell” used in this application includes cells that have a hematopoietic origin and play a role in the immune response. Immune cells include: lymphocytes, such as B lymphocytes and T lymphocytes; Natural killer cells; Myeloid cells, such as monocytes, macrophages, eosinophilic cells, mast cells, basophils, and granulocytes.

[0139] The term “approximate” used in this application means that the index value is within the acceptable error range of the specific value measured by the general technician in this field, and that the value depends in part on how it is measured (that is, the limitation of the measurement system). For example, in each practice in this field, “about” may mean a standard deviation within or above 1. Alternatively, “about” or “substantially included” can imply a range of up to 20 percent. In addition, especially for biological systems or processes, the term may imply at most one order of magnitude or at most five times the value. Unless otherwise stated, the meaning of “about” or “substantially contained” when a particular value appears in this application and claim shall be assumed to be within an acceptable error range for that particular value.

[0140] When referring to ligands/receptors, antibodies/antigens, or other binding pairs, “specific” binding refers to the presence of the binding reaction of the mentioned protein, such as PD-1, in a heterogeneous population of proteins and/or other biological reagents. Thus, under specified conditions, specific ligands/antigens bind to specific receptors/antibodies and do not significantly bind to other proteins present in the sample.

[0141] When the terms “to give” and “to treat” refer to an animal, a person, an experimental subject, a cell, tissue, organ or biological fluid, it means to bring an exogenous drug, therapeutic agent, diagnostic agent or composition into contact with an animal, a person, a treated subject, a cell, tissue, organ or biological fluid. “To give” and “to treat” may mean, for example, therapeutic methods, pharmacokinetic methods, diagnostic methods, research methods and experimental methods. The treatment of cells consists of contacting the reagents with the cells and the reagents with the fluids, wherein the fluids are in contact with the cells. “To give” and “to treat” also imply, for example, in vitro treatment of cells by means of reagents, diagnostics, binding compositions or other cells.

[0142] “Effective dose” includes an amount sufficient to ameliorate or prevent the symptoms or symptoms of a medical disease. Effective dose also refer to quantities sufficient to enable or facilitate diagnosis. The effective dose available to a specific patient may vary depending on a number of factors, such as the disease to be treated, the patient's overall health status, the approach and dose administered, and the severity of side effects. The effective dose may be the maximum dose or regimen administered to avoid significant side effects or toxicity. Monoclonal antibody generation, this invention relates to antibody can be put the DNA in expression vectors, transfection the vectors into the host cell then implement the synthesis of the monoclonal antibodies in a recombinant host cell. The host cells can be E. coli cells, Chinese hamster ovary (CHO) cells or myeloma cells that do not produce additional immunoglobulin. The generation of recombinant antibodies is described in more detail below.

[0143] Appropriate routes of administration include parenteral (e.g., intramuscular, intravenous, or subcutaneous) and oral. Antibodies of the present invention for use in pharmaceutical compositions or in the practice can be administered in a variety of conventional ways, such as oral ingestion, inhalation, topical application, or injection through the skin, subcutaneous, intraperitoneal, parenteral, intraarterial, or intravenous. Antibodies can be administered locally rather than in a systemic way (usually in the form of long-acting formulations or sustained-release formulations), for example by injecting antibodies directly into the site of action. In addition, antibodies can be given in targeted drug delivery systems.

[0144] The term “inhibit”, “treat” or “treatment” used in this invention includes delaying the development of symptoms associated with the disease and/or reducing the severity of these symptoms that the disease will or is expected to develop. The terms also include mitigating existing symptoms, preventing additional symptoms, and mitigating or preventing the underlying causes of those symptoms. Thus, the term implies that beneficial results have been assigned to vertebrate objects suffering from disease.

[0145] The term “therapeutic efficiency dose” or “efficiency dose” used in this article refers to the amount of antibody or its fragment that is effective in preventing or mitigating a disease or condition to be treated when given alone or in combination with another therapeutic agent to cells, tissues or persons being treated. Therapeutic effective dose further refers to the amount of the compound sufficient to cause relief of symptoms, such as to treat, cure, prevent or mitigate the related medical condition, or to increase the rate of treatment, cure, prevention or mitigation of the symptoms. When an individual is given a single active ingredient, the therapeutic efficiency dose refers to that single ingredient. When applied in combination, the therapeutic efficiency dose is the amount of the combination of the active ingredients that produced the therapeutic effect, regardless of whether they were given in combination, continuously or simultaneously. The therapeutic effective dose will usually reduce symptoms by at least 10%; Usually at least 20%; Preferably at least about 30%; Preferred at least 40% and preferred at least 50%.

[0146] The pharmaceutical composition of the present invention may also contain other agents, including but not limited to cytotoxic agents, cell growth inhibitors, antiangiogenic or antimetabolic drugs, tumor-targeting drugs, immunostimulants or immune modulators, or antibodies combined with cytotoxic agents, cell production inhibitors, or other toxic drug conjugates. The drug composition may also be administered in conjunction with other forms of treatment, such as surgery, chemotherapy and radiation therapy.

[0147] Typical veterinarians, experiments, or research subjects include monkeys, dogs, cats, rats, mice, guinea pigs, rabbits, horses, and humans.

[0148] The therapeutic application of the antibody of the invention is as follows:

[0149] Antibodies of the present invention specifically bind to human PD-1/L1 and CTLA4 and can be used to increase, improve, stimulate or up-regulate the immune response. Antibodies of the present invention are particularly suitable for treating patients suffering from diseases that can be treated by increasing the T-cell-mediated immune response. Preferred recipients include patients who need to improve their immune response.

[0150] For cancer, the antibody of the present invention can be used to treat cancer (i.e., inhibit the growth or survival of tumor cells). Preferred cancers for which antibodies of the present invention can inhibit their growth include those that normally respond to immunotherapy, but also those that have not hitherto been associated with immunotherapy. Optimizing for the treatment of cancer of unrestricted examples include melanoma (such as malignant metastatic melanoma), kidney cancer (such as clear cell carcinoma), prostate cancer (such as hormone-refractory prostate cancer, HRPC) and pancreatic carcinoma, breast cancer, colorectal carcinoma, lung cancer (non-small cell lung cancer, for example), esophageal carcinoma, head and neck squamous carcinoma, liver cancer, ovarian cancer, cervical cancer, thyroid cancer, glioblastoma, glioma, leukemia, lymphoma and other malignant tumors. In addition, the present invention includes refractory or recurrent cancers whose growth can be inhibited by the antibody of the present invention.

[0151] The antibody can be used alone or in combination with the following substances: anti-tumor drugs or immunogenics (such as weakened cancer cells), tumor antigens (including recombinant proteins, peptides, and glycogens), antigen-presenting cells such as dendritic cells stimulated by antigens or nucleic acids derived from tumors, immune-stimulating cytokines (e.g. 11-2, IFNa2, GM-CSF and cells transfected with genes encoding immune-stimulating cytokines (such as, but not limited to, GM-CSF)); standard cancer treatment (such as chemotherapy, radiation or surgery); or other antibodies (including, but not limited to, antibodies against: VEGF, EGFR, Her2/neu, VEGF receptor, other growth factor receptor, CD20, CD40, CTLA-4, OX-40, 4-IBB, and ICOS).

[0152] For immunocompromised diseases, the antibody of the present invention can also be used to prevent or treat immunocompromised diseases. Antibodies can be used alone or in combination with drugs to stimulate immune responses to pathogens or polymers. Antibodies can be used to stimulate an immune response to viruses that infect humans, such as, but not limited to, human immunodeficiency virus, hepatitis virus (A, B, or C), Epstein-Barr virus, human cytomegalovirus, human papilloma virus, and herpes virus.

[0153] Antibodies can be used to stimulate an immune response to infections caused by bacterial or fungal parasites and other pathogens. Antibodies can be used to stimulate the immune response and remove the polymers in vivo, and treat alzheimer's disease and other diseases.

[0154] The antibody of the invention to the target includes but is not limited to PD-L1, PD-1, CTLA4, TNF-α, PCSK9, NGF, C5, Aβ, IL-6, IL-17A, IL23A, HGF, CMET, Notch1, CCL11, IL6R, IL-31R, IL-1B, IL-20, CD40, CD47, DKK1/2, TIGIT, 4-1BB, IGF-1R, LL4, PDGFR2, HER3, IGF1/2, RANKL, sclerostin, GCGR, CGRP, ANGPTL3, IL-13, IL-4R, CSF-1R, TFPI, FCGRT, CD47, etc., which can be used to treat cancer, asthma, autoimmune diseases, migraine, Alzheimer's disease, hyperlipidemia, osteoarthritis, cluster headache, osteoporosis and other diseases.

[0155] The following examples further state the contents of the present invention, but shall not be construed as the limitation of the present invention. Without deviating from the spirit and substance of the invention, any modification or substitution of the method, procedure or condition of the invention falls within the scope of the invention.

[0156] If not specifically specified, the technical methods used in examples are conventional methods familiar to the technician in the field. Materials, reagents, etc., used in the following examples can be obtained commercially without special instructions.

Example 1 Analysis and Design of the Low Immunogenic Anti-PD-L1 Monoclonal Antibody with De-ADCC/CDC Activity

[0157] The invention used Pymol to analyze the structure of Atezolizumab of Genentech. The relatively flexible region was found between the variable region and the constant region of the antibody, and the flexible amino acid sequence was inserted into the corresponding region. The insertion of the flexible amino acid sequence can block the mechanical stress transmit from variable area to constant region after the combining of antigen and antibody.

[0158] The Fc and/or complement binding sites in heavy chain of the antibody is not sufficiently exposed to Fc receptor and/or complement without this stress transmission. The insertion of the flexible sequence can weaken the interaction between antibody and NK cells, macrophages or neutrophils, which expressing IgG Fc receptors or complement, leading to the reduced or even eliminated ADCC and CDC activity.

[0159] Specifically, the present invention is based on the restoration of glycosylation by mutating 297 amino acid A back to N of Genentech's Atezolizumab, and then a flexible amino acid sequence was inserted between the heavy chain CDR3 and CH2 regions of IgG1 antibody to block the stress transmission between the variable region and constant region of the antibody after binding the antigen, so as to reduce the ADCC/CDC activity while not significantly increasing the formation of the polymers. The amino acid sequences of the original Atezolizumab sequence with full length of heavy chain and variable region of light chain are shown in SEQ ID NO.1 and 2, respectively.

[0160] The low immunogenicity anti-PD-L1 monoclonal antibody provided by the invention has the heavy chain amino acid sequence of SEQ ID NO.3 and 4, and the light chain amino acid sequence of SEQ ID NO.2, respectively named H-1L0 and H-2L0.

[0161] According to the known information of the glycosylation of the antibody heavy chain, the invention synthesizes the corresponding modified sequence, sequenced the synthesized gene and selects the correct sequence for the next operation. The restriction site was designed as EcoR I+Hind III for both the heavy chain and the light chain. Then the sequences were connected to the expression vectors pEE12.4 and pEE6.4 for heavy chain and light chain respectively. E. coli DH5 was transformed to obtain the expression vector of heavy chain and light chain of antibody. Meanwhile, sequencing and sequence alignment were proceeded for the constructed antibodies. The sequence alignment results of the modified anti-PD-L1 monoclonal antibody with the original Atezolizumab heavy chain were shown in FIG. 1.

Example 2 Analysis and Design of the Anti-PD-1 Monoclonal Antibody with De-ADCC/CDC Activity

[0162] The invention modified the Pembrolizumab of Merck (USA). First, switch the antibody from IgG4 subtype to IgG1 subtype. Then, analyze the structure of the Pembrolizumab with Pymol, the relatively flexible region was found between the variable region and the constant region of the antibody, and the flexible amino acid sequence was inserted into the corresponding region. The invention synthesizes the corresponding modified sequence, sequenced the synthesized gene and selects the correct sequence for the next operation. Monoclonal antibody (H1L0) was generated.

[0163] Specifically, the present invention inserted a flexible amino acid sequence between the heavy chain CDR3 and CH2 regions of IgG1 antibody to block the stress transmission between the variable region and constant region of the antibody after binding the antigen. The Fc and/or complement binding sites in heavy chain of the antibody is not sufficiently exposed to Fc receptor and/or complement without this stress transmission. So the insertion of the flexible sequence can weaken the interaction between antibody and NK cells, macrophages or neutrophils, which expressing IgG Fc receptors or complement, leading to the reduced or even eliminated ADCC and CDC activity. Flexible amino acid sequence was the polypeptide consisting of amino acids with smaller side chains, including but not limited to GGSGGS, GSGGSGG, GSGGSGGG, GGGGSGGG, GSGSG, GGSGG, GGS, GGSGS and GGGS, to prevent or reduce interference in conformation between different domains. The modified heavy chain amino acid sequence according to the method described in the present invention is shown as SEQ ID No.7.

[0164] The invention synthesizes the corresponding modified sequence, sequenced the synthesized gene and selects the correct sequence for the next operation. The restriction site was designed as EcoR I+Hind III for both the heavy chain and the light chain. Then the sequences were connected to the expression vectors pEE12.4 and pEE6.4 for heavy chain and light chain respectively. E. coli DH5 was transformed to obtain the expression vector of heavy chain and light chain of antibody. Meanwhile, sequencing and sequence alignment were proceeded for the constructed antibodies. The sequence alignment results of the modified anti-PD-1 monoclonal antibody with the original Pembrolizumab heavy chain were shown in FIG. 9.

Example 3 Analysis and Design of the Anti-CTLA-4 Monoclonal Antibody with De-ADCC/CDC Activity

[0165] The invention modified the Ipilimumab of Bristol-Myers Squibb (BMS). Analyze the structure of the Ipilimumab with Pymol, the relatively flexible region was found between the variable region and the constant region of the antibody, and the flexible amino acid sequence was inserted into the corresponding region. The invention synthesizes the corresponding modified sequence, sequenced the synthesized gene and selects the correct sequence for the next operation. Monoclonal antibody (H1L0) was generated. Specifically, the present invention inserted a flexible amino acid sequence between the heavy chain CDR3 and CH2 regions of IgG1 antibody to block the stress transmission between the variable region and constant region of the antibody after binding the antigen. The Fc and/or complement binding sites in heavy chain of the antibody is not sufficiently exposed to Fc receptor and/or complement without this stress transmission. So the insertion of the flexible sequence can weaken the interaction between antibody and NK cells, macrophages or neutrophils, which expressing IgG Fc receptors or complement, leading to the reduced or even eliminated ADCC and CDC activity. Flexible amino acid sequence was the polypeptide consisting of amino acids with smaller side chains, including but not limited to GGSGGS, GSGGSGG, GSGGSGGG, GGGGSGGG, GSGSG, GGSGG, GGS, GGSGS and GGGS, to prevent or reduce interference in conformation between different domains. The modified heavy chain amino acid sequence according to the method described in the present invention is shown as SEQ ID No.10.

[0166] The invention synthesizes the corresponding modified sequence, sequenced the synthesized gene and selects the correct sequence for the next operation. The restriction site was designed as EcoR I+Hind III for both the heavy chain and the light chain. Then the sequences were connected to the expression vectors pEE12.4 and pEE6.4 for heavy chain and light chain respectively. E. coli DH5 was transformed to obtain the expression vector of heavy chain and light chain of antibody. Meanwhile, sequencing and sequence alignment were proceeded for the constructed antibodies. The sequence alignment results of the modified anti-CTLA-4 monoclonal antibody with the original Ipilimumab heavy chain were shown in FIG. 13.

Example 4 ADCC Activity Verification of Modified Antibody

[0167] The ADCC activity of the antibody is evaluated by detecting the killing ability of the FcR-TANK cells to the overexpressed cells of target proteins (PD-L1, PD-1 and CTLA-4) in the presence of the relevant antibodies.

[0168] Take the ADCC activity detection of anti-PD-L1 antibody as an example: Using CFSE to dye Raji cells overexpressing target protein (such as PD-L1, PD-1 or CTLA-4), then adjust the Raji and FcR-TANK cell density to 6×10.sup.5/mL respectively. The modified antibody, Atezolizumab and the positive control antibody (Purchased from ImmuneOnco Biopharma) are diluted with a proportional gradient (the highest concentration is 4 μg/mL and triply diluted to 12 gradients with medium).

[0169] Incubate the antibodies, target cells and effector cells together: 50 μL of antibodies with different dilution gradients, 50 μL of target cells and 100 μL of FcR-TANK cells were added to the 96-well plate. Parallel wells were performed for each gradient and two different blank controls (culture medium 150 μL+target cells 50 μL and culture medium 50 μL+target cells 50 μL+FcR-TANK cells 100 μL) were set. Incubate at 37° C., with 5% CO.sub.2 for 4 hours. At the end of incubation, place the plate at room temperature for 10 min, then 5 μg/mL PI was added to stain the dying Raji cells. And the cell populations were analyzed using flow-cytometer. For calculation of ADCC activity: ADCC %=[(Sample % PI Positive cell−Control % PI Positive cell)/(100−Control % PI Positive cell)]×100. The relation curve between ADCC % and concentration is drawn.

[0170] The ADCC activity evaluation results showed the modified anti-PD-L1 monoclonal antibody of the present invention has the same low/no ADCC activity as the original Atezolizumab, as shown in FIG. 3.

[0171] The ADCC activity evaluation results showed that the modified PD-1 monoclonal antibody lost its ADCC activity, while the original Pembrolizumab showed relatively weak ADCC activity, as shown in FIG. 11.

[0172] The ADCC activity evaluation results showed that the ADCC activity of anti-CTLA-4 monoclonal antibody was lost, while the ADCC activity of Ipilimumab was normal, as shown in FIG. 15.

Example 5 Affinity Evaluation of Modified Antibodies

[0173] Plasmid extraction was carried out for the vector constructed in EXAMPLE 1-3 with Qiagen endotoxin-free plasmid extraction kit. The plasmids of different heavy and light chains were randomly combined, and CHO cells were used for transient transfection expression. Protein-based ELISA was used to determine the binding affinity (EC50 value was reported), which can be used to compare the binding ability between the modified and original antibodies.

[0174] ELISA was used to determine the relative binding affinity of antibodies to human PD-L1. PD-L1 was immobilized on the plate at 4° C. overnight, and the non-specific binding site was blocked by incubation with 3% BSA-PBS at room temperature for 1 hour. After coating, the plate was washed with PBS and the diluent of anti-PD-L1 antibodies was prepared, which was incubated with the immobilized protein at 25° C. for 1 hour. After the incubation, the plate was washed with PBS for 3 times, and incubated at 25° C. with binding buffer containing peroxidase-labeled Goat anti-human IgG diluted to 1/2000 for 1 hour. and then washed three times again and add TMB for color development. The ELISA results are shown in FIG. 2. The magnitude of the relative binding affinity is expressed by the semi-maximum binding concentration. Affinity and EC50 were detected for the antibodies (see Table 1). The results showed that the affinity of modified anti-PD-L1 antibody and PD-L1 was similar to that of the original Atezolizumab (see FIG. 2).

TABLE-US-00001 TABLE 1 Evaluation of antibody binding affinity mAb EC.sub.50 (pM) Atezolizumab 320.3 Modified anti-PD-L1 antibody 219.4

[0175] ELISA was used to determine the relative binding affinity of antibodies to human PD-1. PD-1 was immobilized on the plate at 4° C. overnight, and the non-specific binding site was blocked by incubation with 3% BSA-PBS at room temperature for 1 hour. After coating, the plate was washed with PBS and the diluent of anti-PD-1 antibodies was prepared, which was incubated with the immobilized protein at 25° C. for 1 hour. After the incubation, the plate was washed with PBS for 3 times, and incubated at 25° C. with binding buffer containing peroxidase-labeled Goat anti-human IgG diluted to 1/2000 for 1 hour. and then washed three times again and add TMB for color development. The ELISA results are shown in FIG. 10. The magnitude of the relative binding affinity is expressed by the semi-maximum binding concentration. Affinity and EC50 were detected for the antibodies (see Table 2). The results showed that the affinity of modified anti-PD-1 antibody and PD-1 was similar to that of the original Atezolizumab (see FIG. 10).

TABLE-US-00002 TABLE 2 Evaluation of antibody binding affinity mAb EC.sub.50 (pM) Pembrolizumab 54.5 Modified anti-PD-1 antibody 43.7

[0176] ELISA was used to determine the relative binding affinity of antibodies to human CTLA-4. CTLA-4 was immobilized on the plate at 4° C. overnight, and the non-specific binding site was blocked by incubation with 3% BSA-PBS at room temperature for 1 hour. After coating, the plate was washed with PBS and the diluent of anti-CTLA-4 antibodies was prepared, which was incubated with the immobilized protein at 25° C. for 1 hour. After the incubation, the plate was washed with PBS for 3 times, and incubated at 25° C. with binding buffer containing peroxidase-labeled Goat anti-human IgG diluted to 1/2000 for 1 hour. and then washed three times again and add TMB for color development. The ELISA results are shown in FIG. 14. The magnitude of the relative binding affinity is expressed by the semi-maximum binding concentration. Affinity and EC50 were detected for the antibodies (see Table 3). The results showed that the affinity of modified anti-CTLA-4 antibody and CTLA-4 was similar to that of the original Atezolizumab (see FIG. 14).

TABLE-US-00003 TABLE 3 Evaluation of antibody binding affinity mAb EC.sub.50 (pM) Ipilimumab 155.0 Modified anti-CTLA-4 antibody 134.9

Example 6 Bioactivity Evaluation of Modified Anti-PD-1 and Anti-PD-L1 Antibodies

[0177] This method is based on two cell lines, CHO-PD-L1-CD3L cell line and Jurkat-PD-1-NFAT cell line. CHO-PD-L1-CD3L cell line stably expressed PD-L1 and anti-CD3-scFv, which can be used as target cells; The Jurkat-PD-1-NFAT cell line stably expressed PD-1 and luciferase (the luciferase gene was regulated by NFAT elements (transcription factors) (IL-2 promoter)), which can be used as effector cells. The binding of PD-1 and PD-L1 can block the downstream signal transduction of CD3, thus inhibiting the expression of luciferase. When PD-1 antibody or PD-L1 antibody is added, this block effect is reversed, and luciferase can be expressed, thus detecting the fluorescence signal.

[0178] The specific experimental procedures are as follows: [0179] 1. Cell culture: Jurkat-PD-1-NFAT cells were cultured in RPMI1640 medium containing 10% FBS, 1% NEAA and antibiotics. CHO-PD-L1-CD3L cells were cultured in DMEM or F12 medium containing 10% FBS, 1% NEAA and antibiotics. [0180] 2. Cell inoculation: CHO-PD-L1-CD3L cells were seeded in 96-well plates with 50000 cells per well and cultured for 12-14 hours at 37° C. and 5% CO.sub.2. After the removing of the medium, 50 μL analytical medium (RPMI1640 medium containing 2% FBS) with 100,000 Jurkat-PD-1-NFAT cells were added into each well. [0181] 3. Antibody screening: The modified antibody or the original antibody is diluted in a gradient ratio of 1:3 from a concentration of 10 μg/mL (using the analytical medium). The diluted antibodies were then added to each well and incubated at 37° C. with 5% CO.sub.2 for 6 hours. [0182] 4. Add 100 μL Promega Bio-Glotm Luciferase Assay substrate. The relative luciferase activity units were evaluated by the SpectraMax M5.

[0183] The results show that the modified anti-PD-L1 antibody and the original Atezolizumab have similar inhibitory effects on PD-1/PD-L1 (As shown in FIG. 4). The diagram was drawn and the IC50 values of antibodies against the interaction of PD-1 and PD-L1 are calculated, as shown in Table 4.

TABLE-US-00004 TABLE 4 Evaluation of antibody inhibitory effect mAb IC.sub.50 (nM) Atezolizumab 1.988 Modified anti-PD-L1 antibody 1.945

[0184] The results show that the modified anti-PD-1 antibody and the original Pembrolizumab have similar inhibitory effects on PD-1/PD-L1 (As shown in FIG. 12). The diagram was drawn and the IC50 values of antibodies against the interaction of PD-1 and PD-L1 are calculated, as shown in Table 5.

TABLE-US-00005 TABLE 5 Evaluation of antibody inhibitory effect mAb IC.sub.50 (nM) Pembrolizumab 1.986 Modified anti-PD-1 antibody 1.943

Example 7 the Modified Anti-CTLA-4 Antibody Inhibits the Binding of CTLA-4 to CD80 or CD86

[0185] ELISA was used to detect the binding efficiency of CTLA-4 with CD80 or CD86. hCD80 or hCD86 were immobilized on the plate at 4° C. overnight, and the non-specific binding sites were blocked by incubation with 3% BSA-PBS at room temperature for 1 hour. After coating, the plate was washed with PBS and the mixed diluent of anti-CTLA-4 antibody and Biotin-CTLA-4 (biotin-CTLA-4 was a fixed concentration of 1 μg/mL, and the anti-CTLA-4 antibody is gradient diluted with the highest concentration of 1 μg/mL and the lowest concentration of 0 μg/mL) was prepared. The mixed diluent was incubated with the immobilized protein at 25° C. for 1 hour. After the incubation, the plate was washed with PBS for 3 times, and incubated at 25° C. with binding buffer containing peroxidase-labeled Avidin diluted to 1/8000 for 1 hour. And then washed three times again and add TMB for color development. As shown in FIG. 16, anti-CTLA-4 monoclonal antibody of the present invention inhibit the binding of CTLA-4 to CD80 or CD86.

[0186] The CELISA method is used to evaluate the efficacy of the antibody in competition with CD80 and CD86 binding to human CTLA-4 transfected CHO cells. CHO cells expressing hCTLA-4 were first constructed, add 50 μL per well and cultured to 80%-100% coverage of CHO-hCTLA-4 cells in the well. Then, 50 μL mixed diluent containing fixed concentration (1 μg/mL) biotin-CD80 or Biotin-CD86 and different dilution concentrations (the highest concentration is 1 μg/mL, the lowest concentration is 0 μg/mL, gradient dilution) of anti-CTLA-4 antibody was added and incubated at 37° C. for 1 hour. After the incubation, the plate was washed with PBS for 3 times, and incubated at 25° C. with binding buffer containing peroxidase-labeled Avidin diluted to 1/8000 for 1 hour. And then washed three times again and add TMB for color development. The ELISA results are shown in FIG. 17.

Example 8 Immunogenicity Evaluation of Modified Anti-PD-L1 Antibody and Atezolizumab in Mice

[0187] The titer of ADA was evaluated with the serum of modified antibody or Atezolizumab immunized mice by ELISA, respectively. Balb/c mice were used for the experiment with 5 mice in each group. Specific immune procedures were as follows: 1) Basal immunity: the antigen was mixed with The Complete Freud's Adjuvant by the same volume, fully emulsified, and subcutaneously injected at different position; 2) Enhanced immunity: The emulsion of antigens and Incomplete Freud's Adjuvant was used to enhance immunity. The total dose per Balb/c mouse was 70 μg.

[0188] Serum was collected from mice 0 days, 7 days, 14 days and 21 days after immunization to evaluate the titer of ADA, the results was shown in FIG. 5. The results shown that the ADA titer of monoclonal antibody produced by the invention in mice is 80% lower than that of Atezolizumab.

Example 9 Stable Cell Line Construction and the Expression Trial of Modified Anti-PD-L1 Antibody

[0189] The modified anti-PD-L1 antibody of the invention and the original Atezolizumab were simultaneously constructed with CHO stable cell pool, and 5 g of preliminary expression and purification of the modified anti-PD-L1 antibody and the original Atezolizumab were carried out in accordance with the production specifications of antibody drugs known to the public in this field. HPLC-SEC was used to compare the antibodies obtained, as shown in FIG. 6A and FIG. 6B. The sample loading volume (50 μL) and concentration (60 mg/mL) of Atezolizumab and the modified anti-PD-L1 antibody were the same. It can be seen from the figure that, with the same sample loading volume, the main peak area of Atezolizumab was reduced by nearly 10% compared with that of the modified anti-PD-L1 antibody. Therefore, it is demonstrated that there were more polymers in Atezolizumab. Therefore, during the sample loading of HPLC-SEC, the polymers were removed by the filter, resulting in a decrease in the peak area. The HPLC-SEC peak area calculation results of the two antibodies are shown in Table 6. At the same time, HPLC-SEC results showed that the peak position of the modified anti-PD-L1 antibody was further forward than that of the Atezolizumab, which could to be due to the increase in molecular weight of the antibody caused by the restored glycosylation of the antibody.

TABLE-US-00006 TABLE 6 HPLC-SEC results of antibodies mAb RT Area Height % Area Atezolizumab Polymer 28.876 170858 898 0.786 Monomer 32.915 21572737 315915 99.214 Modified Polymer 26.959 124831 883 0.530 anti-PD-L1 Monomer 32.679 23431856 348923 99.470 antibody

Example 10 Glycan Isotype Evaluation of Modified Anti-PD-L1 Antibodies

[0190] Based on the results of EXAMPLE 9, the modified anti-PD-L1 antibodies was further validated for the glycan isotype. It mainly adopts the method of public knowledge in the field: antibodies were first digested with PNGase F (New England Biolabs) according to the manufacturer's instructions, and the free glycan(s) were separated using LudgerClean™ EB10 kit according to the manufacturer's instructions, and the free glycan(s) were analyzed and identified by mass spectrometry. After verification, the Atezolizumab did not detect the N-glycan modification, while the modified anti-PD-L1 antibody was normal glycosylation modification, as shown in FIG. 7. The glycan isotypes of modified anti-PD-L1 antibody are shown in Table 7.

TABLE-US-00007 TABLE 7 The glycan isotypes of modified anti-PD-L1 antibody G0 G0F Man5 G1F(1,6) G1F(1,3) G0FS1 G2F relative 2.52 69.80 0.82 15.10 6.24 0.57 1.76 peak area (%)

Example 11 Stability Verification of Modified Anti-PD-L1 Antibody and Atezolizumab

[0191] The stability of the modified anti-PD-L1 monoclonal antibody and the original Atezolizumab was verified and compared. The modified anti-PD-L1 antibody and the original Atezolizumab were simultaneously subjected to rapid heat treatment, and their stability was verified as follows:

[0192] Two antibodies were taken by the same volume and concentration. The samples were taken after standing at 4° C. for 10 hours. After the first sampling, the two antibodies were placed at 60° C. for 10 minutes. Visually observe the changes in appearance and take samples for the second time. After sampling, the two antibodies were centrifuged at 4° C. at 10000 rpm for 5 minutes to observe whether there was visible precipitation at the bottom of the centrifuge tube, and the supernatant was sampled again. After the third sampling, the supernatant were filtered by 0.2 μm filter and sampled again. After the last sampling, the supernatant after filtration was placed at 4° C. for continuous observation. Antibody concentration and binding affinity of PD-L1 were measured in all samples obtained.

[0193] The PD-L1 binding affinity of the modified anti-PD-L1 antibody and the original Atezolizumab were shown in FIG. 8, and the concentration of each sample of the two antibodies were shown in Table 8. It can be seen that the modified anti-PD-L1 antibody is more stable than Atezolizumab.

TABLE-US-00008 TABLE 8 Stability verification of modified anti- PD-L1 antibody and Atezolizumab Sample Sampling time Concentration (mg/mL) Atezolizumab Before the heat treatment 60.8841 After the heat treatment 60.3778 After centrifugation 56.9252 After filtration 49.1294 Modified Before the heat treatment 59.8288 anti-PD-L1 After the heat treatment 59.3042 antibody After centrifugation 57.2363 After filtration 57.9317

[0194] The present invention screened the modified De-ADCC activity monoclonal antibodies against a number of different targets. They not only maintain the binding affinity to the target protein, but also remove its ADCC activity, and can specifically block the binding of the target protein to its corresponding ligand. At the same time, for the modified anti-PD-L1 antibody, by using the ADCC removing method of the invention, the purpose of removing the ADCC effect is not only achieved, but also the problems of high content of polymers and strong immunogenicity caused by the modification of the original antibody drug were solved.

[0195] The description of the above examples is intended only to assist in understanding the method and its core ideas of the present invention. It should be noted that for technicians in the field, on the premise of not breaking away from the principle of the present invention, some improvements and modifications may also be made to the present invention, and these improvements and modifications may also fall within the protection scope of the claims of the present invention.

INDUSTRIAL APPLICABILITY

[0196] The present invention provides the De-ADCC/CDC activity of monoclonal antibodies and its generation method and applications. The present invention modified the antibody sequences of multi-target sites such as PD-L1, PD-1, CTLA-4, TNF-α, PCSK9, NGF, CD47 and C5, etc. A flexible amino acid sequence was inserted between the heavy chain CDR3 and CH2 regions of IgG1 antibody to block the stress transmission between the variable region and constant region of the antibody after binding the antigen, so as to reduce the ADCC/CDC and other Fc-mediated activities while not significantly increasing the formation of the polymers. The modified antibodies in the present invention and the original antibodies target the same sites, but the antibody subtype or glycosylation state is different. For the modified antibodies in the present invention, the stability is significantly improved or/and immunogenicity is significantly reduced, and the half-life is prolonged for PD-L1 antibody or others. The antibodies modified by the technology of the present invention eliminated the ADCC/CDC and other Fc-mediated activities activity, therefore it can effectively avoid side effects caused by the activation of ADCC/CDC and improve the curative effect. It has excellent clinical application value, high economic value and broad market prospect, and is suitable for promotion.